Description
Introducing the Retatrutide 20mg Pen – a research-grade peptide that acts as a triple-receptor agonist, specifically designed for advanced metabolic research. This groundbreaking compound targets GLP-1, GIP, and glucagon receptors, providing a holistic approach to appetite control, glucose metabolism, and energy expenditure.
Key Features:
• Triple-Receptor Agonist: Engages GLP-1, GIP, and glucagon receptors simultaneously to deliver a comprehensive mechanism of action.
•Research-Grade Purity: Produced to stringent standards to guarantee consistency and reliability in experimental environments.
•Convenient Pen Delivery: Pre-measured, ready-to-use pens facilitate administration and improve dosing accuracy.
Clinical Insights:
In a Phase 2 clinical trial, retatrutide showed significant weight loss over a period of 48 weeks, with participants experiencing average weight changes between -8.7% and -24.2%, depending on the dosage given.
These results indicate retatrutide’s potential effectiveness in weight management strategies.
Retatrutide dosage facts
- Starting dose: 1mg or 2mg weekly (based on phase II trials)
- Dose escalation: Increased every 4 weeks
- Maximum dose: Up to 12mg weekly in trials
- Maintenance dose: Varies by individual (4mg to 12mg in studies)
You must be logged in to post a review.
Reviews
There are no reviews yet.